{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=42",
    "query": {
      "intervention": "Active capsule",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 1418,
    "total_pages": 142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T18:28:19.744Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04325659",
      "title": "An Innovative Intervention for OUD Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Opioid-Related Disorders",
        "Opioid Dependence",
        "Opioid Addiction",
        "Opioid Withdrawal"
      ],
      "interventions": [
        {
          "name": "Bridge Device",
          "type": "DEVICE"
        },
        {
          "name": "Lofexidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sham Bridge Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-11-15",
      "completion_date": "2025-04-20",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04325659"
    },
    {
      "nct_id": "NCT04625595",
      "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomolecular Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-09",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625595"
    },
    {
      "nct_id": "NCT02811939",
      "title": "Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Active Dronabinol",
          "type": "DRUG"
        },
        {
          "name": "Active Pregnenolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo Dronabinol",
          "type": "DRUG"
        },
        {
          "name": "Placebo Pregnenolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2016-04-07",
      "completion_date": "2017-06-09",
      "has_results": false,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02811939"
    },
    {
      "nct_id": "NCT03527472",
      "title": "Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 111,
      "start_date": "2018-08-23",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03527472"
    },
    {
      "nct_id": "NCT06858813",
      "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Cancer",
        "Squamous-Cell Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "ABBV-324",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2025-04-14",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06858813"
    },
    {
      "nct_id": "NCT04663308",
      "title": "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "Volixibat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2020-12-18",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 34,
      "location_summary": "Coronado, California • Los Angeles, California • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04663308"
    },
    {
      "nct_id": "NCT01162850",
      "title": "Oral Polypodium Leucotomos for Melasma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melasma"
      ],
      "interventions": [
        {
          "name": "Polypodium Leucotomos",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2008-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2011-08-05",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01162850"
    },
    {
      "nct_id": "NCT01349868",
      "title": "PT005 MDI Dose Ranging Versus Foradil Aerolizer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT005 MDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate 12 μg (Foradil® Aerolizer®)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate 24 μg (Foradil® Aerolizer®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-09-12",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349868"
    },
    {
      "nct_id": "NCT01844323",
      "title": "A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Palbociclib Formulation Reference",
          "type": "OTHER"
        },
        {
          "name": "Palbociclib Formulation Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-06",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844323"
    },
    {
      "nct_id": "NCT01376297",
      "title": "A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chemotherapy-Induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Netupitant and Palonosetron",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Palonosetron",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Helsinn Healthcare SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2011-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-11-17",
      "last_synced_at": "2026-11-01T18:28:19.744Z",
      "location_count": 11,
      "location_summary": "Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "East Orange",
          "state": "New Jersey"
        },
        {
          "city": "Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376297"
    }
  ]
}